KRAS and pancreatic neoplasm: demonstrated that exosomes carrying CRISPR/Cas9 plasmid DNA may specifically target pancreatic cancer cells with mutant KRAS G12D, leading to the deletion of target genes and the subsequent inhibition of tumor growth.